A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

Lab values

• Hypercalcemia defined as above the institutional normal range (corrected for albumin when albumin levels are below normal)
• History of calcium-related kidney stones
• Creatinine \> 1.5X above upper limit of normal

Other

• The following criteria will prevent inclusion of an inappropriate subject into the trial:
• Osteoporosis requiring prescription treatment
• Known symptomatic primary hyperparathyroidism
• Women who are known to be pregnant or who plan to become pregnant while on rituximab treatment

• Each of the following criteria must be met in order for a patient to be considered eligible for registration:
• Biopsy proven (with hematopathology review at one of the participating sites to confirm correct histology in accordance with World Health Organization) indolent lymphoma to include the following diagnoses:
  • Grade 1, 2, or 3a follicular lymphoma
  • Small lymphocytic lymphoma (CLL excluded)
  • Marginal zone lymphoma (nodal or splenic)
  • Mucosal-associated lymphoid tissue
• Measurable disease defined by Lugano criteria
• No prior anti-lymphoma systemic therapy; prior radiation therapy allowed
• Age 18 or over
• Ann Arbor stages II, III or IV
• Patients with follicular lymphoma must have PET FDG-avid lymphoma and fulfill Low tumor burden by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria:
  • No mass \> 7 cm
  • \< 3 distinct masses of greater than 3 cm
  • No B symptoms
  • No splenomegaly \> 16 cm by computed tomography (CT) scan
  • No risk of vital organ compression
  • No leukemic phase \> 5000/µl circulating lymphocytes (except for in patients with splenic marginal zone diagnosis)
  • No cytopenias (platelets \< 100,000/µl, hemoglobin \< 10 g/dl, or absolute neutrophil count \< 1500/µl)